David OjciusLeveraging intratumoral probiotics for pancreatic cancer #immunotherapy via xenophagy.
#probiotic #microbiology #immunology
https://www.cell.com/cell-host-microbe/abstract/S1931-3128(26)00078-8
David UsharauliCatch-bond interactions are not easy to grasp compared to affinity and specificity. How are they measured, and is the approach reproducible?
GastroAGIπ― HCC treatment is evolvingβ¦
TACE + immunotherapy + targeted therapy shows stronger outcomesβbut are we ready to change practice?
β οΈ Promising data, but guidelines still need phase III confirmation
#GastroAGI #HCC #LiverCancer #TACE #Immunotherapy #TargetedTherapy #Hepatology #Oncology #MedEd
Hans-Cees π³π³π€’π¦ππππππ@xs4me2 Wetenschappers laten deze week zien dat de gezondheid van dit orgaan, ook wel thymus genoemd, verband houdt met levensduur, veroudering, risico op hart- en vaatziekten en kanker
Echte ontdekkings wetenschap waarbij #ai nuttig is ingezet bij een deel van de studie
#kanker #Immunotherapy
neat_newsIn a small study with 12 patients using immunotherapy with a new antibody injected directly into tumors meant for 6 patients that their tumors shrank and for 2 that they went in complete remission. See http://www.neat-news.com/3551.php. #cancer #immunotherapy
Orbit News HubMIIP Protein Blocks Colorectal Cancer Via Control of Immune Response
https://orbitnewshub.com/miip-protein-blocks-colorectal-cancer-via-control-of-immune-response/
#ColorectalCancer #MedicalResearch #Immunotherapy #OrbitNewsHub #HealthNews #CancerResearch
halama_immunoNew publication on the role of #macrophages in shaping the tumor #microenvironment in #cancer ... leading to the exploration of #adipose tissue and it's impact on #innateimmunity and #adaptiveimmunity in #ovariancancer to the point where resistancr to #immunotherapy is observed. These findings are then put into action for patient stratification, showing the utility in #radiology and #medicaloncology and #oncology #Science #medicine #immunology
Howard Smith MD, AMLaser-Aided Immunotherapy For Brain Cancer. Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. #laser #immunotherapy #astrocytoma #cancer
https://www.instagram.com/p/DVt_oDBiVAO/
https://www.instagram.com/p/DVt_oDBiVAO/
Howard G. Smith MD, AM on Instagram: "Laser-Aided Immunotherapy For Brain Cancer Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. Neuro-oncologists at USC report this development in the journal Nature Communications. In this Phase 1/2 clinical trial, 45 patients with recurrent astrocytoma were randomized to receive either laser interstitial thermal therapy (LITT) that destroys tumor tissue and opens the blood-brain barrier plus the immunotherapy with the drug pembrolizumab immunotherapy or standard care, surgery, followed by the immunotherapy. The results are striking: nearly 50% of patients in the LITT group were alive at 18 months, compared with 0% in the standard-treatment group. In addition, more than one-third of LITT-treated patients survived beyond three years, compared to a typical 4β5 month survival seen with surgery and immunotherapy. The addition of of LITT, adding laser therapy to immunotherapy, is a potential game-changing approach. These results are early and require confirmation in larger trials, they offer real hope in a disease with limited therapeutic options and generally poor outcomes. https://doi.org/10.1038/s41467-026-69522-w https://www.news-medical.net/news/20260226/Innovative-laser-procedure-offers-new-hope-for-recurrent-brain-tumors.aspx #laser #immunotherapy #astrocytoma #cancer"
0 likes, 0 comments - drhowardsmithreports on March 10, 2026: "Laser-Aided Immunotherapy For Brain Cancer Adding a laser procedure dramatically improves the results of immunotherapy for one of the deadliest brain cancers. Neuro-oncologists at USC report this development in the journal Nature Communications. In this Phase 1/2 clinical trial, 45 patients with recurrent astrocytoma were randomized to receive either laser interstitial thermal therapy (LITT) that destroys tumor tissue and opens the blood-brain barrier plus the immunotherapy with the drug pembrolizumab immunotherapy or standard care, surgery, followed by the immunotherapy. The results are striking: nearly 50% of patients in the LITT group were alive at 18 months, compared with 0% in the standard-treatment group. In addition, more than one-third of LITT-treated patients survived beyond three years, compared to a typical 4β5 month survival seen with surgery and immunotherapy. The addition of of LITT, adding laser therapy to immunotherapy, is a potential game-changing approach. These results are early and require confirmation in larger trials, they offer real hope in a disease with limited therapeutic options and generally poor outcomes. https://doi.org/10.1038/s41467-026-69522-w https://www.news-medical.net/news/20260226/Innovative-laser-procedure-offers-new-hope-for-recurrent-brain-tumors.aspx #laser #immunotherapy #astrocytoma #cancer".
Cindymy Cancer Team is AWESOME but when patients are sometimes advised to "eat whatever U want" ~ I DISAGREE & Don't comply! My ailing body Needs food that NOURISHES & That certainly isn't going to be a steady supply of junk food that I *want* (occasional treats are okπ).
Oncology doctors are experts on mainstream medical care like #chemotherapy #radiation #immunotherapy , Not #nutrition
They prescribe the most helpful #cancertreatment possible while I manage my grocery list, pantry & kitchen stoveπ
Oncology doctors are experts on mainstream medical care like #chemotherapy #radiation #immunotherapy , Not #nutrition
They prescribe the most helpful #cancertreatment possible while I manage my grocery list, pantry & kitchen stoveπ
Summarized Scienceπ¦ Melanoma - Feb 2026
β’ Personalized mRNA vaccine shows durable reduction in melanoma recurrence
β’ HOXD13 regulates angiogenesis and immune evasion in melanoma
β’ Pepyrus boosts sensitivity in HLA-bound neoantigen discovery
β’ SITC defines consensus criteria for ICI resistance
β’ Vibostolimab adds no benefit over pembrolizumab alone in melanoma
β’ Pathologic response assessment shows high reproducibility across tumor types
